Aclaris Therapeutics Inc (ACRS) Expected to Announce Quarterly Sales of $800,000.00
Equities analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to announce $800,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $600,000.00. The business is expected to announce its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current financial year, with estimates ranging from $680,000.00 to $1.68 million. For the next fiscal year, analysts expect that the business will post sales of $19.57 million per share, with estimates ranging from $12.06 million to $28.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million.
Aclaris Therapeutics (ACRS) traded up $0.44 during mid-day trading on Friday, reaching $24.63. 177,537 shares of the company’s stock were exchanged, compared to its average volume of 427,609. Aclaris Therapeutics has a one year low of $21.32 and a one year high of $33.25. The company has a market capitalization of $759.47, a PE ratio of -11.40 and a beta of 1.96.
Institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its position in shares of Aclaris Therapeutics by 40.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after buying an additional 17,804 shares during the last quarter. Cadence Capital Management LLC acquired a new position in shares of Aclaris Therapeutics during the third quarter valued at about $689,000. Boothbay Fund Management LLC raised its position in shares of Aclaris Therapeutics by 60.3% during the third quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock valued at $535,000 after buying an additional 7,791 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after buying an additional 697,104 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in shares of Aclaris Therapeutics by 620.6% during the third quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock valued at $6,247,000 after buying an additional 208,429 shares during the last quarter. 92.02% of the stock is owned by institutional investors and hedge funds.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.